Chemical radiosensitizers for use in radiotherapy.
Level 5 - mechanism / opinion, no new human data
Narrative review of chemical radiosensitizers and biological mechanisms without systematic search methodology or primary clinical data.
PubMed 17478086 · doi:10.1016/j.clon.2007.03.010
What was done
This narrative review summarizes chemical agents and physiological strategies developed to enhance tumor cell killing during radiotherapy while sparing normal tissues, focusing on mechanisms to overcome radioresistance caused by tumor hypoxia and altered DNA repair.
What was found
The abstract provides a descriptive overview of multiple classes of radiosensitizers and reports no quantitative data or effect sizes. Key approaches summarized include oxygenation strategies (nicotinamide with carbogen), electron-affinic nitroimidazoles (such as nimorazole), hypoxia-specific cytotoxins (tirapazamine), nitric oxide delivery, redox-active gadolinium chelates, halogenated pyrimidines, DNA topoisomerase and repair inhibitors (such as the PARP inhibitor AG14,361), alkylating agents (temozolomide), and molecular agents targeting EGFR, Ras, and COX-2 pathways (including cetuximab, gefitinib, vandetanib, and celecoxib).
Why it matters
The review provides a broad mechanistic categorization of chemical strategies designed to overcome hypoxia-mediated radioresistance and improve the therapeutic ratio of radiation therapy.
Limits
The abstract contains no primary experimental or clinical data, no quantitative outcomes or sample sizes, and does not describe a systematic review methodology. Mechanisms and clinical efficacy vary widely across the numerous drug classes discussed.
Cited by
- supports Hypoxic tumors are less radiosensitive than well-oxygenated tumors.